\-\ Texto\\:\\ \ \(0\)\
\-\ pathology\\:\\ \ \(22\)\
\-\ \\ \\-\\ cd20\\ positive\\ small\\ lymphoid\\ cells\\ and\\ plasmacytic\\ cells\ \(0\)\
\-\ \\ \\-\\ cd3\\ less\\ frequent\\,\\ positive\\ in\\ 1\\/3\\ of\\ lymphoid\\ cells\ \(0\)\
\-\ \\ \\-\\ cd5\\,\\ cd10\\ negative\ \(0\)\
\-\ \\ \\-\\ in\\ situ\\ hybridization\\ \\â\\€\\“\\ monoclonal\\ lambda\\ positive\ \(0\)\
\-\ low\\ grade\\ b\\-cell\\ lymphoma\\ malt\\ type\\ with\\ plasmacytic\\ differentiation\ \(0\)\
\-\ low\\ grade\\ b\\-cell\\ lymphoma\\ malt\\ type\\ with\\ plasmacytic\\ differentiation\ \(0\)\
\-\ radiation\\ to\\ eye\\ and\\ orbit\ \(0\)\
\-\ persistence\\ of\\ subretinal\\ deposits\ \(0\)\
\-\ body\\ and\\ head\\ mri\\ unremarkable\ \(0\)\
\-\ lp\\ normal\ \(0\)\
\-\ vitrectomy\\:\\ scant\\ cells\\ consistent\\ with\\ chronic\\ inflammation\\.\\ \\ no\\ cytologic\\ atypia\\ or\\ monoclonal\\ b\\ cell\\ population\ \(0\)\
\-\ no\\ definite\\ response\\ to\\ systemic\\ steroids\ \(0\)\
\-\ variable\\ visual\\ acuity\\ 20\\/20\\-20\\/40\ \(0\)\
\-\ 94\\ weeks\ \(1\)\
\-\ increasing\\ subretinal\\ fluid\ \(0\)\
\-\ is\\ the\\ choroid\\ a\\ primary\\ site\\ for\\ involvement\\ with\\ lymphoproliferative\\ neoplasms\\?\ \(0\)\
\-\ what\\ is\\ the\\ spectrum\\ of\\ lymphoproliferative\\ neoplasms\\ occurring\\ at\\ that\\ site\\?\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ plasmacytic\\:\\ 0\\.39246041555839284\ \(0\)\
\-\ subretinal\\:\\ 0\\.26164027703892856\ \(0\)\
\-\ cells\\:\\ 0\\.252110941564172\ \(0\)\
\-\ malt\\:\\ 0\\.235360414645507\ \(0\)\
\-\ lymphoproliferative\\:\\ 0\\.2301313042144767\ \(0\)\
\-\ monoclonal\\:\\ 0\\.21548046618608582\ \(0\)\
\-\ lymphoid\\:\\ 0\\.20026167488449376\ \(0\)\
\-\ positive\\:\\ 0\\.16171110261514085\ \(0\)\
\-\ differentiation\\:\\ 0\\.15886243447118245\ \(0\)\
\-\ neoplasms\\:\\ 0\\.15246252053718204\ \(0\)\
\-\ cell\\:\\ 0\\.14038453878188817\ \(0\)\
\-\ site\\:\\ 0\\.13195220158067433\ \(0\)\
\-\ hybridization\\:\\ 0\\.13082013851946428\ \(0\)\
\-\ cd5\\:\\ 0\\.1176802073227535\ \(0\)\
\-\ vitrectomy\\:\\ 0\\.1176802073227535\ \(0\)\
\-\ grade\\:\\ 0\\.1176463515648659\ \(0\)\
\-\ cd3\\:\\ 0\\.11506565210723835\ \(0\)\
\-\ cd10\\:\\ 0\\.11285507717027111\ \(0\)\
\-\ cytologic\\:\\ 0\\.11094019006004312\ \(0\)\
\-\ type\\:\\ 0\\.10975260148947467\ \(0\)\
\-\ cd20\\:\\ 0\\.10925113992472299\ \(0\)\
\-\ lambda\\:\\ 0\\.10925113992472299\ \(0\)\
\-\ atypia\\:\\ 0\\.10925113992472299\ \(0\)\
\-\ scant\\:\\ 0\\.10512567787752776\ \(0\)\
\-\ lp\\:\\ 0\\.09853582273586706\ \(0\)\
\-\ lymphoma\\:\\ 0\\.09743700666870454\ \(0\)\
\-\ persistence\\:\\ 0\\.09518570364781716\ \(0\)\
\-\ low\\:\\ 0\\.09387752994988936\ \(0\)\
\-\ deposits\\:\\ 0\\.09297512871084994\ \(0\)\
\-\ situ\\:\\ 0\\.09106024160062193\ \(0\)\
\-\ acuity\\:\\ 0\\.09106024160062193\ \(0\)\
\-\ 94\\:\\ 0\\.09106024160062193\ \(0\)\
\-\ spectrum\\:\\ 0\\.08303515448113934\ \(0\)\
\-\ occurring\\:\\ 0\\.0825319326194724\ \(0\)\
\-\ definite\\:\\ 0\\.08046334252089864\ \(0\)\
\-\ variable\\:\\ 0\\.07943121723559123\ \(0\)\
\-\ what\\:\\ 0\\.07865587427644588\ \(0\)\
\-\ population\\:\\ 0\\.0773923850881976\ \(0\)\
\-\ choroid\\:\\ 0\\.07671742043695706\ \(0\)\
\-\ orbit\\:\\ 0\\.0757610426827761\ \(0\)\
\-\ response\\:\\ 0\\.07545591730944566\ \(0\)\
\-\ frequent\\:\\ 0\\.07501006736165675\ \(0\)\
\-\ systemic\\:\\ 0\\.07259195838976182\ \(0\)\
\-\ steroids\\:\\ 0\\.0718687622209068\ \(0\)\
\-\ visual\\:\\ 0\\.06979315629463548\ \(0\)\
\-\ inflammation\\:\\ 0\\.06574417630354615\ \(0\)\
\-\ eye\\:\\ 0\\.0654406654710334\ \(0\)\
\-\ increasing\\:\\ 0\\.06442627846251542\ \(0\)\
\-\ pathology\\:\\ 0\\.06421794039341253\ \(0\)\
\-\ with\\:\\ 0\\.06407187365535572\ \(0\)\
\-\ involvement\\:\\ 0\\.05920688700951066\ \(0\)\
\-\ less\\:\\ 0\\.05565164370388268\ \(0\)\
\-\ unremarkable\\:\\ 0\\.05484040497748974\ \(0\)\
\-\ radiation\\:\\ 0\\.054209187367455725\ \(0\)\
\-\ body\\:\\ 0\\.05383668976132822\ \(0\)\
\-\ no\\:\\ 0\\.05320253829483789\ \(0\)\
\-\ and\\:\\ 0\\.05071050674823511\ \(0\)\
\-\ negative\\:\\ 0\\.050643419831766866\ \(0\)\
\-\ primary\\:\\ 0\\.0502997636261655\ \(0\)\
\-\ weeks\\:\\ 0\\.04902589279497438\ \(0\)\
\-\ head\\:\\ 0\\.048788856794485407\ \(0\)\
\-\ chronic\\:\\ 0\\.048555675209159474\ \(0\)\
\-\ of\\:\\ 0\\.04802521018987212\ \(0\)\
\-\ fluid\\:\\ 0\\.04723100932669371\ \(0\)\
\-\ is\\:\\ 0\\.04480438618494677\ \(0\)\
\-\ consistent\\:\\ 0\\.04435523829990381\ \(0\)\
\-\ small\\:\\ 0\\.04219652725862863\ \(0\)\
\-\ mri\\:\\ 0\\.04199018770552476\ \(0\)\
\-\ to\\:\\ 0\\.0409009700765829\ \(0\)\
\-\ in\\:\\ 0\\.040699655586574776\ \(0\)\
\-\ that\\:\\ 0\\.03549925325119269\ \(0\)\
\-\ normal\\:\\ 0\\.03339944608628335\ \(0\)\
\-\ the\\:\\ 0\\.032645158753237\ \(0\)\
\-\ at\\:\\ 0\\.030897871152058973\ \(0\)\
\-\ or\\:\\ 0\\.028457661980389983\ \(0\)\
\-\ for\\:\\ 0\\.024793735066119434\ \(0\)\
